Werewolf Therapeutics reported second-quarter 2026 GAAP earnings per share of $0.08, surpassing analyst expectations by $0.40. Revenue reached $21 million, all from collaboration revenue tied to the sale of its JZP898 program to Jazz Pharmaceuticals Ireland Limited, whereas no collaboration revenue was recorded in the same period last year. Cash and cash equivalents stood at $22 million as of June 30, 2026, down from $46.5 million at the end of March, and the company expects its current operating plan to fund operations into the second quarter of 2027.
Werewolf Therapeutics IncQ2 EPS beat estimates by $0.40, driven by collaboration revenue from JZP898 sale to Jazz Pharmaceuticals.